[PDF][PDF] Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable …
NN Senzer, HL Kaufman, T Amatruda… - Journal of Clinical …, 2009 - academia.edu
NN Senzer, HL Kaufman, T Amatruda, M Nemunaitis, T Reid, G Daniels, R Gonzalez…
Journal of Clinical Oncology, 2009•academia.eduPhase II Clinical Trial of a Granulocyte-Macrophage Colony-Stimulating Factor–Encoding,
Second-Generation Oncolytic Herpesviru Page 1 Phase II Clinical Trial of a Granulocyte-Macrophage
Colony-Stimulating Factor–Encoding, Second-Generation Oncolytic Herpesvirus in Patients
With Unresectable Metastatic Melanoma Neil N. Senzer, Howard L. Kaufman, Thomas
Amatruda, Mike Nemunaitis, Tony Reid, Gregory Daniels, Rene Gonzalez, John Glaspy, Eric
Whitman, Kevin Harrington, Howard Goldsweig, Tracey Marshall, Colin Love, Robert Coffin …
Second-Generation Oncolytic Herpesviru Page 1 Phase II Clinical Trial of a Granulocyte-Macrophage
Colony-Stimulating Factor–Encoding, Second-Generation Oncolytic Herpesvirus in Patients
With Unresectable Metastatic Melanoma Neil N. Senzer, Howard L. Kaufman, Thomas
Amatruda, Mike Nemunaitis, Tony Reid, Gregory Daniels, Rene Gonzalez, John Glaspy, Eric
Whitman, Kevin Harrington, Howard Goldsweig, Tracey Marshall, Colin Love, Robert Coffin …
Purpose
Treatment options for metastatic melanoma are limited. We conducted this phase II trial to assess the efficacy of JS1/34.5-/47-/granulocyte-macrophage colony-stimulating factor (GM-CSF) in stages IIIc and IV disease.
academia.edu